Exenatide modulates expression of metalloproteinases and their tissue inhibitors in TNF-α stimulated human retinal pigment epithelial cells

Garczorz, Wojciech; Gallego‐Colon, Enrique; Kosowska, Agnieszka; Siemianowicz, Krzysztof; Kłych-Ratuszny, Agnieszka; Woźniak, Michał; Aghdam, Mohammad Reza F.; Francuz, Tomasz; Dorecka, Mariola

doi:10.1016/j.pharep.2018.10.003

Cited by 7 publications

(11 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CRT change may also implicate the morphological disruption and dysfunction of the inner or outer blood-retinal barrier during the development of disease. [54][55][56][57][58] There was no significant difference between pegaptanib every 6 weeks and the sham injection group in terms of efficacy and safety, which differs from the results of the VISION trials. 17,59 This finding, together with National Institute for Health and Care Excellence (NICE) guidance, indicated that pegaptanib is not recommended for the treatment of nAMD.…”

Section: Discussioncontrasting

confidence: 72%

See 1 more Smart Citation

Comparative efficacy and safety of anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: systematic review and Bayesian network meta-analysis

Zhao

Wang

et al. 2020

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Background: As a debilitating neurodegenerative disease, neovascular age-related macular degeneration (nAMD) accounts for more than 90% of severe visual loss or legal blindness among AMD patients. Anti-vascular endothelial growth factor (VEGF) had been applied widely in nAMD treatment. To date, debate regarding efficacy and safety still exists among different anti-VEGF regimens as management of nAMD. To provide substantial evidence for clinical nAMD treatment, this study ranks the priority of anti-VEGF regimens via Bayesian network meta-analysis (NMA), comparing data collected from randomized controlled trials (RCTs). Methods: We searched PubMed Central, MEDLINE Ovid, Embase Ovid, ISRCTN, ICTRP and ClinicalTrials. gov from a database established until 1 April 2019 systematically for anti-VEGF regimens. Bayesian NMA with random-effect was conducted to compare efficacy and safety and rank priority of anti-VEGF regimens. The primary efficacy and safety outcomes were the proportion of patients gaining 15 or more letters, and the incidence of arterial thromboembolic (ATC) events. The effect measure is the standard mean difference (SMD), or the odds ratio (OR) with their 95% confidence interval (CI). The study protocol is registered with PROSPERO, number CRD42019132243. Results: We obtained 6467 citations and identified 29 RCTs including 13,596 participants; 86% of these trials were low risk or of uncertain risk bias. In NMA, ORs compared with sham injection for the proportion of patients gaining 15 or more letters (12,699 participants from 23 trials) ranged from 4.05 [95% Bayesian credible interval (CrI) 1.62–10.11] for ranibizumab quarterly regimen to 8.57 (95% CrI 4.66–15.73) for a ranibizumab treat-and-extend regimen. No difference was found between sham injection and anti-VEGF regimens for ATC events (11,500 participants from 18 trials). Results for the primary outcome did not substantially change in sensitivity analyses after removing studies at high risk of bias and small sample size ( n < 100), respectively. Conclusion: The treat-and-extend regimen of ranibizumab and aflibercept are the preferred anti-VEGF regimens for nAMD. Bevacizumab treat-and-extend regimens need more head-to-head comparisons with other regimens or sham injection for advanced application. The treat-and-extend regimen proved to be the most effective regimen for each anti-VEGF drug in the NMA. Pegaptanib every 6 weeks and Conbercept quarterly are unable to satisfy the best corrected visual acuity (BCVA) improvement requirement of nAMD patients.

show abstract

Section: Discussioncontrasting

confidence: 72%

“…CRT change may also implicate the morphological disruption and dysfunction of the inner or outer blood-retinal barrier during the development of disease. 54 – 58 …”

Section: Discussionmentioning

confidence: 99%

Comparative efficacy and safety of anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: systematic review and Bayesian network meta-analysis

Zhao

Wang

et al. 2020

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

show abstract

“…Knee joint synovial tissues were cut into small pieces and digested in 0.05% trypsin for 15 min at 37°C. Cells were treated with 10 ng/mL TNF‐α in the presence or absence of 10 and 20 nM exendin‐4 (an active ingredient form of exenatide) for 24 h.…”

Section: Methodsmentioning

confidence: 99%

Exenatide ameliorates inflammatory response in human rheumatoid arthritis fibroblast‐like synoviocytes

Tao

Wang

et al. 2019

IUBMB Life

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease of unknown etiology characterized by degradation of cartilage and bone, accompanied by unimpeded proliferation of synoviocytes of altered phenotype. In the present study, we investigated the involvement of the glucagon‐like peptide 1 (GLP‐1) receptor on human fibroblast‐like synoviocytes (FLS) in the pathogenesis of RA using the selective GLP‐1 agonist exenatide, a licensed drug used for the treatment of type 2 diabetes. Our results indicate that exenatide may play a role in regulating tumor necrosis factor‐α‐induced mitochondrial dysfunction by increasing mitochondrial membrane potential, oxidative stress by reducing the production of reactive oxygen species, the expression of NADPH oxidase 4, expression of matrix metalloproteinase (MMP)‐3 and MMP‐13, release of proinflammatory cytokines including interleukin‐1β (IL‐1β), IL‐6, monocyte chemoattractant protein‐1, and high‐mobility group protein 1, as well as activation of the p38/nuclear factor of κ light polypeptide gene enhancer in B‐cells inhibitor, α/nuclear factor κB signaling pathway in primary human RA FLS. These positive results indicate that exenatide may have potential as a therapeutic agent for the treatment and prevention of RA. © 2019 IUBMB Life, 9999(9999):1–9, 2019

show abstract

“…It is well known that hyperglycemia induces inflammatory responses in the retina, leading to several changes that include increased expression of adhesion molecules (ICAM-1 and VCAM-1), with consequent increment of monocyte adhesion, upregulation of VEGF-A secretion, metalloproteinases release and rise in ROS production [ 101 , 102 , 103 ]. Several studies demonstrated the protective effects of GLP-1R activation in RPE ( Table 2 ), in particular that exenatide is able to counteract changes caused by inflammatory factors.…”

Section: Rpe Cellsmentioning

confidence: 99%

“…Several studies demonstrated the protective effects of GLP-1R activation in RPE ( Table 2 ), in particular that exenatide is able to counteract changes caused by inflammatory factors. Indeed, exenatide improves viability of RPE cells exposed to TNF-α and high glucose [ 102 , 103 , 104 ]. Moreover, in RPE cells treated with TNF-α, it reduces expression of VCAM and ICAM-1 [ 101 ], and levels of metalloproteinases (MMPs) and, contextually, increases the expression of its inhibitor, TIMP-2 [ 102 ].…”

Section: Rpe Cellsmentioning

confidence: 99%

Anti-Inflammatory Effects of GLP-1R Activation in the Retina

Puddu

Maggi

2022

IJMS

View full text Add to dashboard Cite

Glucagon-like peptide-1 (GLP-1) is an incretin hormone, mainly produced by enteroendocrine L cells, which participates in the regulation of glucose homeostasis, and in reduction in body weight by promoting satiety. Actions of GLP-1 are mediated by activation of its receptor GLP-1R, which is widely expressed in several tissues including the retina. The effects of GLP-1R activation are useful in the management of type 2 diabetes mellitus (T2DM). In addition, the activation of GLP-1R has anti-inflammatory effects in several organs, suggesting that it may be also useful in the treatment of inflammatory diseases. Inflammation is a common element in the pathogenesis of several ocular diseases, and the protective effects of treatment with GLP-1 emerged also in retinal diseases. In this review we highlight the anti-inflammatory effects of GLP-1R activation in the retina. Firstly, we summarized the pathogenic role of inflammation in ocular diseases. Then, we described the pleiotropic effects of GLP-1R activation on the cellular components of the retina which are mainly involved in the pathogenesis of inflammatory retinal diseases: the retinal ganglion cells, retinal pigment epithelial cells and endothelial cells.

show abstract

Exenatide modulates expression of metalloproteinases and their tissue inhibitors in TNF-α stimulated human retinal pigment epithelial cells

Cited by 7 publications

References 41 publications

Comparative efficacy and safety of anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: systematic review and Bayesian network meta-analysis

Comparative efficacy and safety of anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: systematic review and Bayesian network meta-analysis

Exenatide ameliorates inflammatory response in human rheumatoid arthritis fibroblast‐like synoviocytes

Anti-Inflammatory Effects of GLP-1R Activation in the Retina

Contact Info

Product

Resources

About